Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Pharmacogenet Genomics
; 26(7): 334-9, 2016 07.
Article
em En
| MEDLINE
| ID: mdl-27058883
ABSTRACT
OBJECTIVE:
Pharmacogenomic studies have established the important contribution of drug-metabolizing enzyme genotype toward drug toxicity and treatment failure; however, clinical implementation of pharmacogenomics has been slow. The aim of this study was to systematically review the information on drug-metabolizing enzyme pharmacogenomics available in the US drug labeling, practice guidelines, and recommendations.METHODS:
Drug-metabolizing enzyme genotype and phenotype information was assessed in US FDA drug labeling, clinical practice guidelines, and independent technology assessors to evaluate the consistency in information sources for healthcare providers.RESULTS:
Eighty four gene-drug pairs were identified as having drug-metabolizing enzyme genotype or phenotype information within the label. The manner in which pharmacogenomic information was presented was heterogeneous both within the label and between clinical practice recommendations.CONCLUSION:
For proper implementation of pharmacogenomics in clinical practice, information sources for healthcare providers should relay consistent and clear information for the appropriate use of biomarkers.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Preparações Farmacêuticas
/
Guias de Prática Clínica como Assunto
/
Sistema Enzimático do Citocromo P-450
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos